Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ofatumumab + ifosfamide + carboplatin + etoposide
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Ofatumumab + ifosfamide + carboplatin + etoposide is a combination chemotherapy regimen used primarily as a second-line treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), grade 3b follicular lymphoma, and transformed follicular lymphoma. Ofatumumab is a monoclonal antibody targeting CD20 on B lymphocytes. Ifosfamide is an alkylating agent that interferes with DNA replication. Carboplatin is a platinum-based chemotherapeutic that causes DNA crosslinking and apoptosis. Etoposide inhibits topoisomerase II, leading to DNA strand breaks and cell death. This combination aims to improve outcomes in patients who have failed first-line therapies such as R-CHOP[1][2][3].
- Brand names
- Toposar
- Other names
- ICE regimen with ofatumumabofatumumab-ICE
02
Targets
Beyond the preview
Go deeper on ofatumumab + ifosfamide + carboplatin + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ofatumumab + ifosfamide + carboplatin + etoposide.